Indian Journal of Medical Microbiology IAMM  | About us |  Subscription |  e-Alerts  | Feedback |  Login   
  Print this page Email this page   Small font sizeDefault font sizeIncrease font size
 Home | Ahead of Print | Current Issue | Archives | Search | Instructions  
Users Online: 103 Official Publication of Indian Association of Medical Microbiologists 
 ~ Next article
 ~ Previous article 
 ~ Table of Contents
 ~  Similar in PUBMED
 ~  Search Pubmed for
 ~  Search in Google Scholar for
 ~Related articles
 ~  Article in PDF (82 KB)
 ~  Citation Manager
 ~  Access Statistics
 ~  Reader Comments
 ~  Email Alert *
 ~  Add to My List *
* Registration required (free)  

 ~  Abstract
 ~  Materials and Me...
 ~  Results
 ~  Discussion
 ~  Acknowledgements
 ~  References
 ~  Article Figures
 ~  Article Tables

 Article Access Statistics
    PDF Downloaded704    
    Comments [Add]    
    Cited by others 41    

Recommend this journal


Year : 2006  |  Volume : 24  |  Issue : 3  |  Page : 208-211

Occurrence of extended spectrum beta-lactamases among Enterobacteriaceae spp. isolated at a tertiary care institute

1 Discovery Research, Dr. Reddy's Laboratories Ltd., Hyderabad - 500 049, India
2 Department of Microbiology, Nizam's Institute of Medical Sciences, Hyderabad - 500 082, Andhra Pradesh, India

Correspondence Address:
M S Kumar
Discovery Research, Dr. Reddy's Laboratories Ltd., Hyderabad - 500 049
Login to access the Email id

Source of Support: None, Conflict of Interest: None

PMID: 16912442

Rights and PermissionsRights and Permissions

 ~ Abstract 

Increasing resistance to third generation cephalosporins has become a cause for concern especially among Enterobacteriaceae that cause nosocomial infections. The prevalence of extended spectrum β -lactamases (ESBLs) among members of Enterobacteriaceae constitutes a serious threat to current β -lactam therapy leading to treatment failure and consequent escalation of costs. A detailed study was initiated to identify the occurrence of ESBLs among the Enterobacteriaceae isolates at a tertiary care hospital using the double disk potentiation technique. Antibiogram profiles were determined to commonly used antibiotics and confirmation of ESBLs production was carried out by the disk diffusion assay using ceftazidime and cefotaxime in the presence and absence of clavulanic acid. Our results indicate that the majority of ESBLs were expressed in Escherichia coli.

Keywords: Aztreonam, cefotaxime, ceftazidime, clavulanic acid, E. coli, ESBLs, K. pneumoniae

How to cite this article:
Kumar M S, Lakshmi V, Rajagopalan R. Occurrence of extended spectrum beta-lactamases among Enterobacteriaceae spp. isolated at a tertiary care institute. Indian J Med Microbiol 2006;24:208-11

How to cite this URL:
Kumar M S, Lakshmi V, Rajagopalan R. Occurrence of extended spectrum beta-lactamases among Enterobacteriaceae spp. isolated at a tertiary care institute. Indian J Med Microbiol [serial online] 2006 [cited 2020 Nov 28];24:208-11. Available from:

Among the wide array of antibiotics, β -lactams are the most varied and widely used agents accounting for over 50% of all systemic antibiotics in use.[1] The most common cause of bacterial resistance to β -lactam antibiotics is the production of β -lactamases. Many of the second and third generation penicillins and cephalosporins were specifically designed to resist the hydrolytic action of major β -lactamases. However, new β -lactamases emerged against each of the new classes of β -lactams that were introduced and caused resistance. The latest in the arsenal of these enzymes has been the evolution of extended spectrum β -lactamases (ESBLs). These enzymes are commonly produced by many members of Enterobacteriaceae , especially E. coli and K. pneumoniae and efficiently hydrolyze oxyimino-cephalosporins conferring resistance to third generation cephalosporins such as cefotaxime, ceftazidime and ceftriaxone and to monobactams such as aztreonam.[2] First isolated in 1983 in Germany, ESBLs spread rapidly to Europe, US and Asia and are now found all over the world.[3] Being plasmid mediated, they are easily transmitted among members of Enterobacteriaceae thus facilitating the dissemination of resistance not only to β -lactams but to other commonly used antibiotics such as quinolones and aminoglycosides.

ESBLs have emerged as a major problem in hospitalized patients worldwide and have been involved in epidemic outbreaks in many institutions in Europe and USA and constitute a serious threat to the current β -lactam therapy as these enzymes cause resistance to most penicillins, cephalosporins and aztreonam.[4] Typically, nosocomial outbreaks were associated with previous antibiotic therapy, especially ceftazidime monotherapy. Hospital colonization by ESBL producing bacteria is usually a complex phenomenon involving many different mechanisms, dissemination of several epidemic strains and dissemination of plasmids and resistant genes.[5] Specific risk factors include prolonged hospital stay, severity of illness, ICU, urinary or arterial catheterization, intubation and mechanical ventilation. ESBLs commonly occur in surgical wards as well as most other areas of the hospital and frequently from patients from extended care facilities.[6]

Since ESBL positive isolates show false susceptibility to expanded spectrum cephalosporins in standard disk diffusion tests[7] it is difficult to reliably detect ESBL production by the routine disk diffusion techniques. Specific detection methods such as double disk potentiation methods recommended by NCCLS[8] have to be adopted. ESBLs are inhibited by β -lactamase inhibitors like clavulanic acid, sulbactam and tazobactam and this property of specific inhibition can be utilized for the detection and confirmation of ESBLs.

There have been few published reports regarding occurrence of ESBLs from the Indian subcontinent and most of the reports dealt with phenotypic identification of ESBLs.[9],[10] This study was initiated to identify the incidence of ESBLs among Enterobacteriaceae isolated over a 12 month period at Nizam's Institute of Medical Sciences (NIMS), a tertiary care hospital at Hyderabad, India.

 ~ Materials and Methods Top

Clinical isolates

A total of 1699 Enterobacteriaceae spp. culture isolates from different clinical specimens during the period of March 2000 to February 2001, were screened for potential ESBL activity. Based on routine antibiotic disk sensitivity tests, isolates that exhibited intermediate/resistance to any one of the third generation cephalosporins, ceftazidime/ cefotaxime were short listed to detect and confirm ESBL producers. Purified cultures were identified by both conventional and Enterorapid 24 test, a Micro-well ID system (Mikro Test- Lachema). E. coli ATCC 25922, ATCC 35218 and K. pneumoniae ATCC 70063 were used as controls to validate the susceptibility tests.


The following antibiotic sensitivity disks used for primary screening were purchased from Hi-Media India: cefotaxime 30 mg, ceftazidime 30 mg, amoxicillin+ clavulanic acid (20 mg+10 mg). Antibiotic powders were kindly provided by the following companies: ceftazidime and lithium clavulanate- SmithKlineBeecham UK, ceftriaxone sodium, cefotaxime, ampicillin, amoxicillin- Ranbaxy Laboratories India, cefaperazone, cefixime, cefadroxil, cephalexin- Orchid Chemicals India, ciprofloxacin- Dr. Reddy's Laboratories India and gentamicin and chloramphenicol was procured from Sigma.

Screening for ESBLs by double disk synergy test

cultures that exhibited intermediate/resistance to third generation cephalosporins were screened to detect ESBL producers. A modified double disk synergy test (disk approximation test) first described by Jarlier[11] was carried out, amoxicillin+clavulanic acid (20 mg+10 mg) disk was placed in the centre and the ceftazidime (30 mg) and cefotaxime (30 mg) disks were placed on either side at a distance of 15 mm centre to centre from the amoxicillin+clavulanic disk. Plates were incubated at 35C for 18-20 hours and the pattern of zones of inhibition was noted. Isolates that exhibited a distinct shape/size with potentiation towards amoxicillin+clavulanic disks were considered potential ESBL producers and short listed for confirmation of ESBL producers.

Phenotypic confirmatory test by disk diffusion assay

ESBL production was confirmed among potential ESBL producing isolates by phenotypic tests. Sensitivity disks containing third generation cephalosporins with and without clavulanic acid were prepared as follows: ceftazidime 30 mg(Ca), ceftazidime+clavulanic acid 10 mg (Ca +), cefotaxime 30 mg (Ce), cefotaxime+clavulanic acid 10 mg (Ce+); and aztreonam 30 mg (AZT), aztreonam+clavulanic acid 10 mg (AZT+). Disk diffusion assay was carried out as per guidelines of NCCLS[8] and differences in zone diameters between disks with and without clavulanic acid were recorded.

Susceptibility profile (MIC) against select ESBL isolates

Minimum inhibitory concentration (MIC) tests were carried out by broth micro dilution[12] to determine the susceptibility profile of all K. pneumoniae (n=47) and select E. coli (n=43) against different classes of antibiotics.

 ~ Results Top

One thousand and six thousand and ninety-nine Enterobacteriaceae spp. were recovered from different clinical specimens like blood, urine and exudates submitted for routine microbiological analysis from both in and out patients of the hospital during the period March 2000 to February 2001. Data was analyzed by Whonet software to sort the identity and source of 1699 Enterobacteriaceae isolates. Three hundred and thirty-six out of 1699 (19.8%) Enterobacteriaceae isolates were identified as potential ESBL producers by the double disk potentiation test. The figure demonstrates the response seen by the position of the disks. The table describes the different species that were identified as ESBL producers among the clinical isolates. The identity of the ESBL positive isolates was as follows: E. coli with 63.7% (214/336) was the largest group followed by K. pneumoniae 14% (47/336), Citrobacter spp. 11.3% (38/336) and all the other species together comprised 11% while 14% (47/336) were isolated from blood, 39% (131/336) were from urine and 47% (158/336) were from exudates.

Phenotypic confirmation of ESBLs was carried out by disk diffusion assay as per the recommendations of NCCLS.[8] The zone of inhibition of the antibiotic alone was compared with the zone of inhibition in combination with clavulanic acid. According to NCCLS recommendations a difference of 5 mm increase in zone diameter for either agent tested in combination with clavulanic acid versus its zone diameter when tested alone confirms the presence of ESBLs. K. pneumoniae (n=47) and E. coli (n=43) exhibited a clear difference of 8 mm in zone diameter to ceftazidime/cefotaxime and aztreonam in combination with clavulanic acid.

Minimum Inhibitory Concentration (MIC) of select ESBL isolates

Forty-seven isolates of K. pneumoniae were resistant to cefazolin, cefoperazone and ampicillin (MIC 256 mg/mL) and 92% of the isolates exhibited MIC of 256 mg/mL against cefadroxil. Eighty-five percent of K. pneumoniae exhibited an MIC of 256 mg/mL to cefotaxime compared to 53% towards ceftazidime and 87% ceftriaxone. MIC of 83% of isolates was 256 mg /mL for gentamicin. Ciprofloxacin exhibited sensitivity wherein the MIC of 21% of isolates was 0.125 mg/mL, 10% showed MIC of 2 mg/mL and the MIC of remaining isolates was in the range of 16-256 mg /mL.

The sensitivity profile of E. coli (n=43) was almost similar to K. pneumoniae , all the isolates were resistant to ampicillin, cefazolin, cefoperazone and cefadroxil. More E. coli (95%) isolates were resistant to cefotaxime compared to 37% to ceftazidime (MIC 256 mg/mL). Twenty-eight percent of the isolates were sensitive to gentamicin (MIC 0.125 mg/mL) while MIC of the rest of isolates was in the range of 64-256 mg/mL. For ciprofloxacin MIC ranged from 64-256 mg/mL.

 ~ Discussion Top

There have been sporadic reports of ESBLs from major hospitals in India and some of them have recorded the incidence to be as high as 60-68%[13],[14] but the sample numbers have been low. Our study indicates that 19.8% Enterobacteriaceae spp. (336/1699) isolated over a period of one year, were ESBLs producers. The unusually high incidence of ESBLs should be a cause of concern to the regulators of the hospital antibiotic policy. Over reliance on third generation cephalosporins to treat gram negative infections is one of the prime factors responsible for increased resistance to this class of antibiotics.

ESBLs have been predominantly reported among K. pneumoniae both in Europe and USA.[2] However, in our study analysis of the 336 confirmed ESBL isolates revealed that ESBLs were predominantly present among E. coli (63.7%) compared to K. pneumoniae (14%) and other Enterobacteriaceae spp. Our findings are similar to that of Ananthakrishnan et al[10] who reported a high prevalence of ESBLs among E. coli . The high incidence of ESBLs among E. coli may be peculiar to the Indian subcontinent.

While double disk potentiation test was a simple and convenient method to detect ESBLs, a phenotypic confirmatory test as recommended by NCCLS[8] is mandated to confirm the presence of ESBLs. Enterobacteriaceae spp. that exhibit resistance to any one of the third generation cephalosporins must be reported as resistant to all third generation cephalosporins. ESBLs are plasmid mediated and multidrug resistance is a characteristic feature of strains producing ESBLs. Our study confirms this observation, as ESBL isolates of K. pneumoniae and E. coli were resistant to different classes of antibiotics. Gentamicin and tobramycin typically demonstrate poor in vitro activity against ESBL producing organisms.[15] Such resistant isolates pose serious problems to the physicians as therapeutic options are limited. Carbapenams and cephamycins are uniformly active against ESBL positive isolates. Monitoring and judicious usage of extended spectrum cephalosporins, periodic surveillance of antibiotic resistance patterns and efforts to decrease empirical antibiotic therapy would go a long way in addressing some of the problems associated with ESBLs.

An interesting observation was the increased resistance of K. pneumoniae and E. coli isolates to cefotaxime as compared to ceftazidime, 85-95% of the K. pneumoniae and E. coli were resistant to cefotaxime (MIC 256 mg/mL) compared to 37-53% that were resistant to ceftazidime. We presume that the major ESBL enzyme being expressed in our isolates is a cefotaximase that preferentially hydrolyses cefotaxime. Further studies are warranted to establish the presence of cefotaximases.

 ~ Acknowledgements Top

We are thankful to Management, Discovery Research, Dr. Reddy's Laboratories Ltd. for providing the facilities to carry out the project.

 ~ References Top

1.Bronson JJ, Barrett JF. Quinolone, Everninomycin, Glycylcycline, Carbapenem, Lipopeptide and Cephem Antibacterials in Clinical Development. Curr Med Chem 2001; 8 :1775-93.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Jacoby GA, Mediros AA. More extended-spectrum β -lactamases. Antimicrob Agents Chemother 1991; 35: 1697-704.  Back to cited text no. 2    
3.Kliebe C, Nies BA, Meyer JF, Tolxdorff- Neutzling RM, Weidemann B. Evolution of plasmid coded resistance to broad spectrum cephalosporins Antimicrob Agents Chemother 1985; 28: 302-7.  Back to cited text no. 3    
4.Thomson KS, Sanders CC. Detection of extended-sprectrum β -lactamases in members of the family Enterobacteriaceae: Comparison of the double disk and three dimensional tests. Antimicrob Agents Chemother 1992; 36 :1877-82.  Back to cited text no. 4    
5.De Champs C, Sirot D, Chanal C, Bonnet R, Sirot J. A 1998 survey of Extended spectrum β-lactamases in Enterobacteriaceae in France. Antimicrob Agents Chemother 1998; 44 :3177-9.   Back to cited text no. 5    
6.Weiner J, Quinn JP, Bradford PA, Goering RV, Nathen C, Bush K. Multiple antibiotic resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999; 281 :517-23.  Back to cited text no. 6    
7.Revati G. Detection of extended spectrum β-lactamases using E-test ESBL strip. Indian J Med Microbiol 1997; 15: 69-71.  Back to cited text no. 7    
8.National Committee for Clinical Laboratory Standards. Performance standards for Antimicrobial Disk susceptibility Tests; Approved standard M2-A7 National Committee for Clinical Laboratory Standards, Wayne, PA; 2000.  Back to cited text no. 8    
9.Revathi G, Singh S. Detection of expanded-spectrum cephalosporin resistance due to inducible lactamases in hospital isolates. J Med Microbiol 1997; 15 :113-115  Back to cited text no. 9    
10.Ananthakrishnan AN, Kanungo R, Kumar A, Badrinath S. Detection of Extended spectrum β-lactamases producers among surgical wound infections and burns patients in JIPMER. Indian J Med Microbiol 2000; 18 :160-5.  Back to cited text no. 10    
11.Jarlier V, Nicolas MH, Fourier G, Phillippon A. Extended broad spectrum β -lactamases conferring transferable resistance to newer β -lactam agents in Enterobacteriaceae, hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10 :867-78.  Back to cited text no. 11    
12.National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grows aerobically. Approved standard M7-A5 National Committee for Clinical Laboratory Standards, Wayne, PA; 2000.  Back to cited text no. 12    
13.Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum beta lactamase producing bacteria in a tertiary care hospital . Indian J Med Res 2002; 115 :153-7.  Back to cited text no. 13    
14.Jones RN, Rhomberg PR, Varman DJ, Mathai D. A comparison of the antimicrobial activity of meropenem and selected broad-spectrum antimicrobials tested against multi-drug resistant Gram negative bacilli including bateraemic Salmonella Spp: Initial studies for MYSTIC programme in India. Int J Antimicrob Agents 2002; 20 :426-31.  Back to cited text no. 14    
15.Spanu T, Luzzaro F, Perilli M, Amicosante G, Toniolo A, Fadda G. Italian ESBLs study group. Occurrence of Extended spectrum β -lactamases in members of family Enterobacteriaceae in Italy. Implication of resistance to β lactams and other antimicrobial agents. Antimicrob Agents Chemother 2002; 46 :196-202.  Back to cited text no. 15    


[Figure - 1]


[Table - 1]

This article has been cited by
1 The beta lactam antibiotics as an empirical therapy in a developing country: An update on their current status and recommendations to counter the resistance against them
Thakuria, B. and Lahon, K.
Journal of Clinical and Diagnostic Research. 2013; 7(6): 1207-1214
2 Assessing the curative property of Moringa oleifera and investigating its mechanism of action against urinary tract infection
Jasmine, R. and Aishwarya, S. and Senthamil Selvi, J. and Chitra and Selvakumar, B.N.
International Journal of PharmTech Research. 2013; 5(2): 562-567
3 Study of extended-spectrum β-lactamase-producing bacteria from urinary tract infections in Bangladesh
Khan, S.A. and Feroz, F. and Noor, R.
Tzu Chi Medical Journal. 2013; 25(1): 39-42
4 Extended-spectrum β-lactamase/AmpC-producing uropathogenic Escherichia coli from HIV patients: Do they have a low virulence score?
Padmavathy, K. and Padma, K. and Rajasekaran, S.
Journal of Medical Microbiology. 2013; 62(PART3): 345-351
5 Plasmid profile of isolated Klebsiella species in a tertiary hospital in Abeokuta, Ogun State, Nigeria
Akingbade, O.A. and Ogiogwa, I.J. and Okonko, I.O. and Okerentugba, P.O. and Innocent-Adiele, H.C. and Nwanze, J.C. and Onoh, C.C.
World Applied Sciences Journal. 2013; 21(3): 371-378
6 Application of WHONET in the antimicrobial resistance surveillance of uropathogens: A first user experience from Nepal
Ghosh, A.N. and Bhatta, D.R. and Ansari, M.T. and Tiwari, H.K. and Mathuria, J.P. and Gaur, A. and Supram, H.S. and Gokhale, S.
Journal of Clinical and Diagnostic Research. 2013; 7(5): 845-848
7 The detection of ESBL-producing Escherichia coli in patients with symptomatic urinary tract infections using different diffusion methods in a rural setting
Harwalkar, A. and Sataraddi, J. and Gupta, S. and Yoganand, R. and Rao, A. and Srinivasa, H.
Journal of Infection and Public Health. 2013; 6(2): 108-114
8 ESBL, MBL and Ampc β lactamases producing superbugs - Havoc in the intensive care units of Punjab India
Oberoi, L. and Singh, N. and Sharma, P. and Aggarwal, A.
Journal of Clinical and Diagnostic Research. 2013; 7(1): 70-73
9 Sensitivity of urinary pathogens to antimicrobial therapy in patients from primary health care [Osetljivost urinarnih patogena na antimikrobnu terapiju kod pacijenata u primarnoj zdravstvenoj zaštiti]
Matic, S. and Ninkovic, V. and Arsovic, A. and Obrenovic, N. and Baskic, D.
Medicinski Casopis. 2012; 46(3): 126-131
10 Antibacterial resistance and trend of urinary tract pathogens to commonly used antibiotics in kashmir valley
Tantry, B.A. and Rahiman, S.
West Indian Medical Journal. 2012; 61(7)
11 The antibiotic resistance profiles of bacterial strains isolated from patients with hospital-acquired bloodstream and urinary tract infections
Ghadiri, H. and Vaez, H. and Khosravi, S. and Soleymani, E.
Critical Care Research and Practice. 2012; 2012(890797)
12 Frequency of extended-spectrum β-lactamase (ESBL)-producing Gram-negative bacilli in a 200-bed multi-specialty hospital in Vellore district, Tamil Nadu, India
Sankar, S. and Narayanan, H. and Kuppanan, S. and Nandagopal, B.
Infection. 2012; 40(4): 425-429
13 Antibiotic susceptibility and multi-drug resistance of escherichia coli isolates producing CTX-M and TEM type beta-lactamases in Mashhad, Iran, in 2010
Moghadam, N.M. and Forghanifard, M.M.
Journal of Kerman University of Medical Sciences. 2012; 19(4): 375-383
14 Effectiveness of combination drugs in extended spectrum beta lactamases producing gram negative isolates- Experience in a tertiary care hospital of Uttarakhand
Khanduri, A. and Thakuria, B. and Gupta, P.
International Journal of Pharma and Bio Sciences. 2012; 3(3): B251-B260
15 The antibiotic sensitivity pattern of Esherichia coli isolated from street vendored vegetable salad in Umuahia, Nigeria
Edward, K.C. and Chikwem, C.
Journal of Pure and Applied Microbiology. 2012; 6(2): 659-664
16 Etiologic profile and antimicrobial susceptibility of community-acquired urinary tract infection in two Cameroonian towns
Akoachere, J.-F.T.K. and Yvonne, S. and Akum, N.H. and Seraphine, E.N.
BMC Research Notes. 2012; 5(219)
17 Management of community-acquired acute bacterial cystitis in Turkey [Türkiyede toplum kökenli akut baktriyel sistit tedavisi]
Coşkun, O. and Erdem, H. and Avci, A.
Turkish Journal of Medical Sciences. 2011; 41(1): 149-157
18 Extended-spectrum beta-lactamase-mediated resistance among bacterial isolates recovered from ocular infections
Bharathi, M.J. and Ramakrishnan, R. and Ramesh, S. and Murugan, N.
Ophthalmic Research. 2011; 47(1): 52-56
19 Occurrence of extended spectrum β-lactamases among E. coli and Klebsiella pneumoniae isolated from urinary tract infection from tertiary health care center in Amravati District
Ghanwate, N. and Thakare, P.V. and Bhise, P.R. and Wandhre, A.
Biosciences Biotechnology Research Asia. 2011; 8(2): 849-852
20 Susceptibility pattern of extended spectrum ß-lactamase producing isolates in various clinical specimens
Roshan, M. and Ikram, A. and Mirza, I.A. and Malik, N. and Abbasi, S.A. and Alizai, S.A.
Journal of the College of Physicians and Surgeons Pakistan. 2011; 21(6): 342-346
21 Incidence of beta lactamases in gram negative bacilli in diabetic foot infection and the impact on the selection of antimicrobial therapy
Vinodkumar, C.S. and Srinivasa, H. and Basavarajappa, K.G. and Bandekar, N.
Journal of Pure and Applied Microbiology. 2011; 5(1): 123-129
22 Extended spectrum β-lactamase producing Enterobacteriaceae & antibiotic co-resistance
Rudresh, S.M. and Nagarathnamma, T.
Indian Journal of Medical Research. 2011; 133(1): 116-118
23 Extended spectrum β-lactamase producing Enterobacteriaceae & antibiotic co-resistance
Rudresh, S.M., Nagarathnamma, T.
Indian Journal of Medical Research. 2011; 133(1): 116-118
24 Changing microbiological profile of pathogenic bacteria in diabetic foot infections: Time for a rethink on which empirical therapy to choose?
Ramakant, P., Verma, A.K., Misra, R., Prasad, K.N., Chand, G., Mishra, A., Agarwal, G., (...), Mishra, S.K.
Diabetologia. 2011; 54(1): 58-64
25 Nosocomial outbreak of septicaemia in neonatal intensive care unit due to extended spectrum β-lactamase producing Klebsiella pneumoniae showing multiple mechanisms of drug resistance
Rastogi, V., Nirwan, P.S., Jain, S., Kapil, A.
Indian Journal of Medical Microbiology. 2010; 28(4): 380-384
26 Extended spectrum -β-lactamase mediated resistance in Escherichia coli in a tertiary care hospital in Kashmir, India
Ahmed, K. and Thokar, M.A. and Toboli, A.S. and Fomda, B.A. and Bashir, G. and Maroof, P.
African Journal of Microbiology Research. 2010; 4(24): 2720-2728
27 Microbial evaluation and public health implications of urine as alternative therapy in clinical pediatric cases: Health implication of urine therapy
Ogunshe, A.A.O. and Fawole, A.O. and Ajayi, V.A.
Pan African Medical Journal. 2010; 5
28 Nosocomial outbreak of septicaemia in neonatal intensive care unit due to extended spectrum β-lactamase producing Klebsiella pneumoniae showing multiple mechanisms of drug resistance
Rastogi, V. and Nirwan, P.S. and Jain, S. and Kapil, A.
Indian Journal of Medical Microbiology. 2010; 28(4): 380-384
29 Extended spectrum beta - lactamases in clinical isolates of Klebsiella pneumoniae in a tertiary care hospital, Chennai-South India
Anbumani and Mallika
Biomedicine. 2010; 30(1): 25-29
30 Extended spectrum beta - Lactamase (ESBL) mediated resistance to antibiotics among Klebsiella pneumoniae in Enugu metropolis
Iroha, I.R. and Egwu, O.A. and Ngozi, A.T. and Chidiebube, N.A. and Chika, E.P.
Macedonian Journal of Medical Sciences. 2009; 2(3): 196-199
31 Extended spectrum beta - Lactamase (ESBL) mediated resistance to antibiotics among Klebsiella pneumoniae in Enugu metropolis
Iroha, I.R., Egwu, O.A., Ngozi, A.T., Chidiebube, N.A., Chika, E.P.
Macedonian Journal of Medical Sciences. 2009; 2(3): 196-199
32 Resistance to third-generation cephalosporins and other antibiotics by Enterobacteriaceae in Western Nigeria
Makanjuola, O.
American Journal of Infectious Diseases. 2009; 5(1): 17-20
33 The prevalence of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae among clinical isolates from a general hospital in Iran
Bazzaz, B.S.F., Naderinasab, M., Mohamadpoor, A.H., Farshadzadeh, Z., Ahmadi, S., Yousefi, F.
Acta Microbiologica et Immunologica Hungarica. 2009; 56(1): 89-99
34 Multiplex PCR for blaCTX-M & blaSHV in the extended spectrum beta lactamase (ESBL) producing gram-negative isolates
Jemima, S.A., Verghese, S.
Indian Journal of Medical Research. 2008; 128(3): 313-317
35 Emerging antibiotic resistance in bacteria with special reference to India
Raghunath, D.
Journal of Biosciences. 2008; 33(4): 593-603
36 Detection of extended spectrum beta-lactamase from clinical isolates in Davangere
Sridhar Rao, P., Basavarajappa, K., Krishna, G.
Indian Journal of Pathology and Microbiology. 2008; 51(4): 497-499
37 Prevalence of extended spectrum beta lactamase and AmpC beta lactamase producers among Escherichia coli isolates in a tertiary care hospital in Jaipur
Sinha, P., Sharma, R., Rishi, S., Sharma, R., Sood, S., Pathak, D.
Indian Journal of Pathology and Microbiology. 2008; 51(3): 367-369
38 Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in diabetic foot infections
Varaiya, A., Dogra, J., Kulkarni, M., Bhalekar, P.
Indian Journal of Pathology and Microbiology. 2008; 51(3): 370-372
39 Prevalence of extended-spectrum β-lactamases among Escherichia coli and Klebsiella pneumoniae isolates in a tertiary care hospital
Agrawal, P., Ghosh, A., Kumar, S., Basu, B., Kapila, K.
Indian Journal of Pathology and Microbiology. 2008; 51(1): 139-142
40 A study of antibiotic sensitivity pattern in gram-negative urinary isolates with special reference to extended spectrum beta lactamase producers
Jaiswal, S., Kastury, N., Kapoor, A.K., Tiwari, A.R., Bhargava, A.
Biomedicine. 2007; 27(4): 162-167
41 Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India
Akram, M., Shahid, M., Khan, A.U.
Annals of Clinical Microbiology and Antimicrobials. 2007; 6: Art No 4


Print this article  Email this article
Previous article Next article


2004 - Indian Journal of Medical Microbiology
Published by Wolters Kluwer - Medknow

Online since April 2001, new site since 1st August '04